Stories written by
Rebecca Aicheler, The Conversation
-
A new antibody treatment may offer protection against severe Covid-19 for up to 18 months
AstraZeneca's durable monoclonal antibody treatment has shown promise in phase 3 clinical trials.
Rebecca Aicheler, The Conversation
-
Why you shouldn’t skip the second dose of your Covid-19 vaccine
Research suggests a single dose of the AstraZeneca is only 33% protective against the Delta variant.
Rebecca Aicheler, The Conversation